BG106083A - Заместени бициклични хетероарилни съединения катоинтегрин-антагонисти - Google Patents

Заместени бициклични хетероарилни съединения катоинтегрин-антагонисти

Info

Publication number
BG106083A
BG106083A BG106083A BG10608301A BG106083A BG 106083 A BG106083 A BG 106083A BG 106083 A BG106083 A BG 106083A BG 10608301 A BG10608301 A BG 10608301A BG 106083 A BG106083 A BG 106083A
Authority
BG
Bulgaria
Prior art keywords
linkage
optionally substituted
direct bond
compounds
alkylene
Prior art date
Application number
BG106083A
Other languages
English (en)
Inventor
David KLARK
Paul EASTWOOD
Neil Harris
Clive Mccarthy
Andrew Morley
Stephen PICKETT
Original Assignee
Aventis Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9908355.2A external-priority patent/GB9908355D0/en
Application filed by Aventis Pharma Limited filed Critical Aventis Pharma Limited
Publication of BG106083A publication Critical patent/BG106083A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Изобретението се отнася до физиологично активни съединения с обща формула@R1Z1 - Het - L1 - Ar1 - L2 - Y@в която Het по-специално е наситена или изцяло ненаситена 8- до 10-членна бициклична система, съдържаща най-малко един хетероатом, избран от O, S или N; R1 е евентуално заместен арил, хетероарил, алкил, алкенил или алкинил, циклоалкил или хетероциклоалкил; Z1 означава директна връзка, алкиленова верига, NR4, O или S(O)n; L1 e -R5-R6-мост, където R5 е алкилен, алкенилен или алкинилен и R6 е директна връзка, циклоалкилен, хетероциклоалкилен, арилен, хетероарилдиил, -С(=Z3)-N4-, -NR4-C(=Z3)-,-Z3-, -C(=O)-, -C(=NOR4)-, -NR4-, -NR4-C(=Z3)-NR4-, -SO2-NR4-, -NR4-SO2-, -O-C(=O)- -C(=O)-O-, -NR4-C(=O)-O- или -O-C(=O)NR4; L2 e директна връзка илимост, представляващ евентуално заместен алкилен,алкенилен, алкинилен, циклоалкенилен, циклоалкилен, хетероаридиил, хетероциклоалкилен или арилен, -[C(=O)-N(R9)-C(R4)(R10)]р-, -Z4-R11-, -C(=O)-CH2- C(=O)-, -R11-Z4-R11-, или -L3-L4-L5; Y e карбокси-или биоизостерна група. Изобретението се отнася идо съответните N-оксиди и пролекарства, както и до фармацевтично приемливите соли и солвати (например хидрати) на тези съединения и техните N-оксидиипролекарства. Съединенията имат ценни фармацевтични свойства, по-специално способност да регулират взаимодействието на VCAM-1 и фибронектин с интегрин VLA-4 (алфа4бета1).
BG106083A 1999-04-12 2001-11-05 Заместени бициклични хетероарилни съединения катоинтегрин-антагонисти BG106083A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9908355.2A GB9908355D0 (en) 1999-04-12 1999-04-12 Chemical compounds
US14147099P 1999-06-29 1999-06-29
PCT/GB2000/001393 WO2000061580A1 (en) 1999-04-12 2000-04-12 Substituted bicyclic heteroaryl compounds as integrin antagonists

Publications (1)

Publication Number Publication Date
BG106083A true BG106083A (bg) 2002-05-31

Family

ID=26315408

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106083A BG106083A (bg) 1999-04-12 2001-11-05 Заместени бициклични хетероарилни съединения катоинтегрин-антагонисти

Country Status (24)

Country Link
US (1) US6706738B2 (bg)
EP (1) EP1183254B1 (bg)
KR (1) KR20010110750A (bg)
CN (1) CN1350534A (bg)
AT (1) ATE286896T1 (bg)
AU (1) AU769554B2 (bg)
BG (1) BG106083A (bg)
BR (1) BR0010599A (bg)
CA (1) CA2369728A1 (bg)
CZ (1) CZ20013661A3 (bg)
DE (1) DE60017389T2 (bg)
EE (1) EE200100528A (bg)
ES (1) ES2231179T3 (bg)
HK (1) HK1044937A1 (bg)
HR (1) HRP20010732A2 (bg)
HU (1) HUP0200803A3 (bg)
IL (2) IL145748A0 (bg)
MX (1) MXPA01010231A (bg)
NO (1) NO20014951L (bg)
NZ (1) NZ514602A (bg)
PL (1) PL351433A1 (bg)
SK (1) SK14372001A3 (bg)
TR (1) TR200102959T2 (bg)
WO (1) WO2000061580A1 (bg)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430978C (en) 2000-12-28 2012-05-15 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
PT1499311E (pt) * 2002-03-29 2010-03-10 Novartis Vaccines & Diagnostic Benzazois substituídos e sua utilização como inibidores da raf cinase
TWI340134B (en) 2003-07-24 2011-04-11 Daiichi Seiyaku Co Cyclohexanecarboxylic acids
AU2005206571B8 (en) 2004-01-23 2010-09-02 Amgen Inc. Compounds and methods of use
AU2005207946A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
AU2005277582A1 (en) * 2004-08-16 2006-03-02 The Procter & Gamble Company 2-(amino or substituted amino)-5, 6-substituted phenol compounds, dyeing compositions containing them, and use thereof
DE102004041137A1 (de) * 2004-08-25 2006-03-02 Wella Ag o-Aminophenol-Derivate und diese Verbindungen enthaltende Färbemittel
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
AU2005312048B2 (en) 2004-11-30 2012-08-02 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
US7514460B2 (en) 2004-12-22 2009-04-07 4Sc Ag Benzazole analogues and uses thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
MX2008013427A (es) 2006-04-19 2008-11-04 Novartis Ag Compuestos de benzoxazole y benzotiazole sustituidos-6-0 y metodos para inhibir la señalizacion csf-1r.
US7931838B2 (en) * 2006-08-31 2011-04-26 Virginia Tech Intellectual Properties, Inc. Method for making oriented single-walled carbon nanotube/polymer nano-composite membranes
CA2703257C (en) * 2007-10-29 2013-02-19 Amgen Inc. Benzomorpholine derivatives and methods of use
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8674113B2 (en) 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
HUE057168T2 (hu) 2013-03-15 2022-04-28 Protagonist Therapeutics Inc A hepcidin analógjai és ezek alkalmazása
SI3143037T1 (sl) 2014-05-16 2021-11-30 Protagonist Therapeutics, Inc. Antagonisti integrin alpha4beta7 tioeterskih peptidov
US9624268B2 (en) 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
SG11201702553RA (en) 2014-10-01 2017-04-27 Protagonist Therapeutics Inc NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3432906A4 (en) 2016-03-23 2020-04-01 Protagonist Therapeutics, Inc. METHOD FOR SYNTHETIZING ALPHA4BETA7 PEPTIDE ANTAGONISTS
WO2019051494A1 (en) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND USES THEREOF
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP3997105A4 (en) 2019-07-10 2023-09-13 Protagonist Therapeutics, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES
MX2022008741A (es) 2020-01-15 2022-10-03 Janssen Biotech Inc Inhibidores de peptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
JP2023525047A (ja) 2020-05-06 2023-06-14 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害薬としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
KR20230110570A (ko) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL123164A (en) * 1995-08-30 2001-03-19 Searle & Co Meta-guanidine urea thiourea or azacyclic amino benzoic acid derivatives and pharmaceutical compositions containing them
AU765294B2 (en) * 1998-04-10 2003-09-11 G.D. Searle & Co. Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
EP1153017B1 (en) * 1999-02-16 2006-05-03 Aventis Pharma Limited Bicyclic compounds and their use as integrin receptor ligands

Also Published As

Publication number Publication date
CN1350534A (zh) 2002-05-22
AU769554B2 (en) 2004-01-29
ES2231179T3 (es) 2005-05-16
SK14372001A3 (sk) 2002-06-04
HUP0200803A3 (en) 2002-12-28
DE60017389T2 (de) 2006-03-02
DE60017389D1 (de) 2005-02-17
NO20014951D0 (no) 2001-10-11
NZ514602A (en) 2003-06-30
HUP0200803A2 (hu) 2002-07-29
WO2000061580A1 (en) 2000-10-19
ATE286896T1 (de) 2005-01-15
AU3981600A (en) 2000-11-14
PL351433A1 (en) 2003-04-22
MXPA01010231A (es) 2003-07-21
IL145748A0 (en) 2002-07-25
IL145748A (en) 2007-02-11
HK1044937A1 (zh) 2002-11-08
HRP20010732A2 (en) 2002-12-31
CA2369728A1 (en) 2000-10-19
CZ20013661A3 (cs) 2002-01-16
BR0010599A (pt) 2002-02-13
NO20014951L (no) 2001-12-11
US20020173506A1 (en) 2002-11-21
US6706738B2 (en) 2004-03-16
TR200102959T2 (tr) 2002-04-22
EP1183254A1 (en) 2002-03-06
EE200100528A (et) 2003-02-17
EP1183254B1 (en) 2005-01-12
KR20010110750A (ko) 2001-12-13

Similar Documents

Publication Publication Date Title
BG106083A (bg) Заместени бициклични хетероарилни съединения катоинтегрин-антагонисти
ES8604203A1 (es) Un procedimiento para la preparacion de nuevas-n-heterociclil-4-piperidinaminas.
NZ221112A (en) Bicyclic aromatic compounds and pharmaceutical compositions
FI881985A (fi) Foerfarande foer framstaellning av terapeutiskt verkande (s,s,s)-isomerer av substituerade acylderivat av 1,2,3,4-tetrahydroisokinolin-3-karboxylsyror.
FI96857B (fi) Menetelmä valmistaa farmakologisesti käyttökelpoista tiatsoliyhdistettä
NZ238181A (en) N-(1-substituted-piperidinyl(alkyl))carbamic acid, urea and carboxamide derivatives and homologues thereof; preparatory processes and pharmaceutical compositions
ES2053587T3 (es) Nuevos derivados de bencimidazoles activos como agentes anti-ulcera.
ES8606306A1 (es) Un procedimiento para preparar nuevos derivados de benzo- triazol- y benzoxazolamina
WO2000068223A8 (en) Ureas and their use as cell adhesion modulators
DE60041487D1 (de) Substituierte bizyclische verbindungen
YU71501A (sh) Supstituisana biciklična heteroaril jedinjenja kao antagonisti integrina
WO2000068195A3 (en) Substituted pyrrolidines as cell adhesion inhibitors
EP0666263A4 (bg)
ATE109485T1 (de) Derivate von n-(vincristinyl-23) und n- (noranhydro-5-vinblastinyl-23) von amino-1- methylphosphonsäure, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen.